Anticoagulants Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Drug Class (Vitamin K antagonists (coumarin anticoagulants), Low molecular weight heparins (LMWH), Direct Oral Anticoagulants (DOACs), Others), By Application (Atrial Fibrillation, Heart Attacks, Deep Vein Thrombosis, Pulmonary Embolism, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online), And By Geography - Forecasts From 2022 To 2027

The anticoagulants market was estimated at US$43.719 billion in 2020.

The anticoagulant market is anticipated to propel at a decent CAGR throughout the forecast period due to a significant increase in the number of people with cardiovascular disease coupled with a growth in the number of cases of venous thromboembolism and arterial thrombosis. Anticoagulants are medicines used to prevent blood clots, especially for high-risk people. These medicines are taken by high-risk people who are more susceptible to clots to reduce the chances of them developing heart conditions of serious nature such as heart attacks and strokes. Blood clots are blood seals that can block the blood vessels of the body and further stop the blood from reaching the crucial organs of the body if they are formed in the wrong place. These organs include the brain, lungs, and heart, among others. The clots can further damage the organ to function properly as they also stop the flow of oxygen to that particular organ.

Diseases such as atrial fibrillation can also lead to the formation of blood clots which can lead to conditions such as heart failure, strokes, and other complications related to the heart. There is a significant increase in the prevalence of obesity around the globe which is also contributing the heart diseases related to blood clots. Furthermore, the risk of clotting in older people is also high due to weaker immune systems and other organs. Thus, the rising proportion of the obese population along with a noteworthy increase in the global geriatric population are some of the key factors which are anticipated to drive the demand for these medicines in the coming years and propel the growth opportunities for the market to surge throughout the forecast period and beyond. Additionally, these medicines are also given to patients during heart-related surgery for the prevention of clot formation. Therefore, the growing number of heart surgeries worldwide is also expected to augment the market growth for anti-coagulants in the next five years. The use of these medicines helps the patient by preventing the clotting process, which is increasing its adoption across the globe. These medicines are sometimes also referred to as blood thinners.

Rising prevalence of heart diseases

The growing number of people diagnosed with heart disease is the primary driver of the anti-coagulants market. According to the World Health Organization (WHO), 17.9 million people die each year due to cardiovascular diseases (CVDs), an estimated 31% of all deaths worldwide. Increasing consumption of tobacco, unhealthy diet and physical inactivity are raising the risk of heart attacks and strokes. According to the Centres for Disease Control and Prevention, heart disease has been the major cause of death in the United States in which coronary heart disease is the most common type of heart disease. The rising obese population is one major cause of heart attacks. All these factors are driving the demand anticipated to propel the demand for these medicines across the globe as doctors are focusing on a combination of risk factors for these diseases, implementing medical screening for individuals at risk, and then providing effective treatment to prevent disability and death while improving quality of life. Also, these medicines are suitable for patients who suffered a heart attack as these medicines lower the risks of another heart attack. Furthermore, a growing number of heart attacks propel the demand for these medicines. For instance, as per the U.S. Department of Health and Human Services, every year, 725,000 people have a heart attack, out of which approximately 30% are those people who have already had a heart attack. Thereby positively impacting the anti-coagulants market growth during the forecast period and beyond.

Deep Vein Thrombosis holds a notable share

Based on application, the global anticoagulants market has been segmented into atrial fibrillation, heart attacks, deep vein thrombosis, pulmonary embolism, and others. The deep vein thrombosis segment is anticipated to hold a significant share owing to its high incidence in developing countries. According to the U.S. Department of Health and Human Services, the prevalence of deep vein thrombosis accounts for 2 per 1000 people each year in the United States.

Furthermore, the anti-coagulants market for atrial fibrillation is anticipated to show notable growth over the forecast period because this disease increases the risks of heart attacks, stroke, and heart failure due to the formation of blood clots. Also, the growing prevalence of this disease across the globe is a key factor expected to bolster the demand for anti-coagulants and thereby positively impact market growth in the coming years.

North America to hold a noteworthy share

Geographically, the global anticoagulants market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. These regions have been further segmented into countries that hold a significant share in the market. North America is expected to hold a significantly large share of this market. The growth in this region is majorly attributed to state-of-the-art healthcare infrastructure, which is expected to continue improving as industry players continue to funnel considerable investments in this sector in these regions. The market in the Asia Pacific is being driven by supportive initiatives by some governments to make expensive healthcare services accessible for people of all income groups.

Recent Developments

• Asundexian, an oral Factor Xia inhibitor from Bayer under phase 2 testing as an anticoagulant with potential safety advantages over existing medications, was given fast-track designation by the US Food and Drug Administration in February 2022.
• The Food and Drug Administration approved dabigatran etexilate (Pradaxa) anticoagulant oral pellets in June 2021 as the first oral anticoagulant to treat children with venous thromboembolism who is 3 months old to under 12 years old after they got at least five days of treatment with a blood thinner administered intravenously.
• In September 2020, Mylan revealed that it paid Aspen US$756 million to expand the line of sterile injectable anticoagulants available in Europe. This agreement supports the company's expansion into hospitals and the future expansion of its biosimilars franchise in Europe.
• A generic form of apixaban, an oral anticoagulant that blocks factor Xa directly to prevent the generation of thrombin and the formation of blood clots, was introduced by Teva UK in June 2022. It will be made available to adults with non-valvular atrial fibrillation (NVAF) and one or more risk factors as a prophylactic medication for stroke and systemic embolism.
• In September 2020, Mylan N.V. declared that it has signed a contract to buy the European thrombosis business of Aspen Pharmacare Holdings Limited. The company has gained a position as the second-largest provider of injectable anticoagulant medications to patients in Europe as a result of this transaction.

COVID-19 Impact on Anticoagulants Market

The COVID-19 outbreak is anticipated to have a significant influence on the anticoagulant business. As per an analysis published in the American Journal of Cardiovascular Drugs in 2020, there are currently more than ten clinical trials evaluating the potential of anticoagulants in COVID-19 patients. Additionally, research is being done on parenteral administration techniques for these medications for use in critically ill COVID-19 patients. In February 2021, the Stony Brook study found that reducing mortality in critically ill COVID-19 Patients with an anticoagulant medication based on blood serum D-dimer levels. As a consequence, the COVID-19 pandemic is anticipated to have an impact on the market both directly and indirectly. Furthermore, individuals with COVID-19, both verified and presumed, ought to have accessibility to follow-up care with low-dose anticoagulants, as per the World Health Organization Update from January 2021. As a result, during COVID-19, the demand for anticoagulants is expected to rise.

1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Anti-Coagulants Market Analysis, By Drug Class
5.1. Introduction
5.2. Vitamin K antagonists (coumarin anticoagulants) 
5.3. Low molecular weight heparins (LMWH)
5.4. Direct Oral Anticoagulants (DOACs)
5.5. Others

6. Anti-Coagulants Market Analysis, By Application
6.1. Introduction
6.2. Atrial Fibrillation
6.3. Heart Attacks
6.4. Deep Vein Thrombosis
6.5. Pulmonary Embolism
6.6. Others

7. Anti-Coagulants Market Analysis, By Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy 
7.3. Retail Pharmacy 
7.4. Online 

8. Anti-Coagulants Market Analysis, By Geography
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. South Korea
8.6.4. India
8.6.5. Indonesia
8.6.6. Taiwan
8.6.7. Others

9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles
10.1. Aspen Holdings
10.2. Bayer AG
10.3. Boehringer Ingelheim International GmbH
10.4. Pfizer Inc.
10.5. Johnson & Johnson Services, Inc.
10.6. Bristol Myers Squibb Company
10.7. Alexion Pharmaceuticals, Inc.
10.8. Daiichi Sankyo, Inc. 
10.9. Anthos Therapeutics
10.10. AcelRx Pharmaceuticals, Inc.